Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sundrug Co.,Ltd. (9989.T)
JPY3,809.00
-29.00 (-0.76%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
1-38-1, Wakamatsucho 183-0005
Fuchu, JP
Fuchu, JP
CEO
Hiroshi Sadakata
Website
sundrug.co.jp
IPO
2001-01-04
ISIN JP3336600006
Also trades on
Other OTC · SDGCF (USD)
Tokyo Stock Exchange · 9989.T (JPY)
Description
Sundrug Co.,Ltd. is a Japanese retail entity primarily focused on operating and managing drugstores and prescription-filling pharmacies throughout the country. Diversifying its retail footprint, the company also oversees a network of discount stores that feature an extensive array of general merchandise. These outlets provide customers with a broad selection, including fresh and packaged foods, personal care products, cosmetics, clothing, household appliances, vehicle accessories, sporting equipment, alcoholic beverages, and even kerosene, in addition to over-the-counter pharmaceutical items. The enterprise was founded in 1957 and its corporate headquarters are located in Fuchu, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY3,809.00
-29.00 (-0.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
493.0K
Beta
0.11
Float Shares
67.82M
Free Float %
58.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11% | +0.73% | -2.27% | -10.67% | -11.72% | -12.67% | -17.59% | -11.80% | +4.87% | -12.93% | +720.60% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,809.00
DCF (Unlevered)
6,432.37
+68.9%
DCF (Levered)
4,010.81
+5.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
57% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.54
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+5.1% Q1'26: +4.3% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+2.1% Q1'26: +3.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+2.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+5.6% Q1'26: +2.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+12.2% ★ Q1'26: +5.9% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.74× ★ Q1'26: 1.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 7 EPS Ana. |
Mar 2027 5 Rev. Ana. 5 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
445.82B
est: 446.84B (-0.2%)
|
503.77B
est: 502.09B (+0.3%)
|
528.39B
est: 529.25B (-0.2%)
|
564.22B
est: 562.92B (+0.2%)
|
588.07B
est: 587.91B (+0.0%)
|
617.77B
est: 614.62B (+0.5%)
|
634.31B
est: 635.12B (-0.1%)
|
648.73B
est: 649.97B (-0.2%)
|
690.46B
est: 689.27B (+0.2%)
|
751.78B
est: 764.20B (-1.6%)
|
801.81B
est: 801.58B (+0.0%)
|
841.98B
833.02B – 881.66B
+5.0% YoY
|
907.48B
890.13B – 925.82B
+7.8% YoY
|
952.28B
917.15B – 1.01T
+4.9% YoY
|
970.80B
943.33B – 1.01T
+1.9% YoY
|
1.01T
985.31B – 1.06T
+4.4% YoY
|
| EBITDA |
32.15B
est: 32.64B (-1.5%)
|
39.44B
est: 36.67B (+7.6%)
|
41.34B
est: 38.65B (+6.9%)
|
43.87B
est: 41.11B (+6.7%)
|
43.48B
est: 42.94B (+1.3%)
|
44.97B
est: 44.89B (+0.2%)
|
46.01B
est: 46.39B (-0.8%)
|
44.26B
est: 47.47B (-6.8%)
|
49.52B
est: 50.34B (-1.6%)
|
56.24B
est: 68.84B (-18.3%)
|
61.89B
est: 72.20B (-14.3%)
|
75.84B
75.04B – 79.42B
+5.0% YoY
|
81.74B
80.18B – 83.39B
+7.8% YoY
|
85.78B
82.61B – 91.35B
+4.9% YoY
|
87.45B
84.97B – 91.23B
+1.9% YoY
|
91.34B
88.75B – 95.29B
+4.4% YoY
|
| EBIT |
25.92B
est: 24.71B (+4.9%)
|
33.03B
est: 27.76B (+19.0%)
|
34.06B
est: 29.26B (+16.4%)
|
36.08B
est: 31.13B (+15.9%)
|
35.23B
est: 32.51B (+8.4%)
|
36.61B
est: 33.99B (+7.7%)
|
37.35B
est: 35.12B (+6.3%)
|
34.05B
est: 35.94B (-5.3%)
|
37.45B
est: 38.11B (-1.7%)
|
41.00B
est: 45.32B (-9.5%)
|
44.50B
est: 47.53B (-6.4%)
|
49.93B
49.40B – 52.28B
+5.0% YoY
|
53.81B
52.78B – 54.90B
+7.8% YoY
|
56.47B
54.39B – 60.14B
+4.9% YoY
|
57.57B
55.94B – 60.06B
+1.9% YoY
|
60.13B
58.43B – 62.73B
+4.4% YoY
|
| Net Income |
16.36B
est: 15.81B (+3.5%)
|
21.57B
est: 20.61B (+4.6%)
|
23.31B
est: 23.23B (+0.4%)
|
24.83B
est: 24.93B (-0.4%)
|
23.93B
est: 24.14B (-0.9%)
|
23.69B
est: 25.15B (-5.8%)
|
25.33B
est: 25.60B (-1.0%)
|
23.85B
est: 24.55B (-2.8%)
|
25.70B
est: 26.31B (-2.3%)
|
29.13B
est: 29.52B (-1.3%)
|
30.75B
est: 31.40B (-2.1%)
|
31.71B
30.31B – 32.28B
+1.0% YoY
|
34.47B
33.74B – 36.14B
+8.7% YoY
|
36.57B
34.37B – 39.54B
+6.1% YoY
|
36.50B
35.20B – 38.60B
-0.2% YoY
|
38.18B
36.78B – 40.33B
+4.6% YoY
|
| SGA |
82.31B
est: 69.10B (+19.1%)
|
90.87B
est: 77.64B (+17.0%)
|
96.51B
est: 81.84B (+17.9%)
|
104.62B
est: 87.04B (+20.2%)
|
111.67B
est: 90.91B (+22.8%)
|
118.00B
est: 95.04B (+24.2%)
|
120.88B
est: 98.21B (+23.1%)
|
122.45B
est: 100.51B (+21.8%)
|
134.50B
est: 106.58B (+26.2%)
|
148.32B
est: 143.22B (+3.6%)
|
142.31B
est: 150.22B (-5.3%)
|
157.80B
156.12B – 165.23B
+5.0% YoY
|
170.07B
166.82B – 173.51B
+7.8% YoY
|
178.47B
171.88B – 190.05B
+4.9% YoY
|
181.94B
176.79B – 189.82B
+1.9% YoY
|
190.03B
184.66B – 198.26B
+4.4% YoY
|
| EPS |
133.48
est: 135.14 (-1.2%)
|
178.43
est: 176.24 (+1.2%)
|
197.32
est: 198.59 (-0.6%)
|
212.31
est: 213.16 (-0.4%)
|
204.75
est: 206.41 (-0.8%)
|
202.67
est: 215.01 (-5.7%)
|
216.67
est: 218.84 (-1.0%)
|
204.02
est: 209.90 (-2.8%)
|
219.83
est: 214.32 (+2.6%)
|
249.06
est: 252.38 (-1.3%)
|
262.90
est: 256.92 (+2.3%)
|
268.44
259.08 – 275.91
+4.5% YoY
|
294.60
288.42 – 308.99
+9.7% YoY
|
310.58
293.85 – 337.98
+5.4% YoY
|
312.40
300.91 – 329.98
+0.6% YoY
|
326.40
314.39 – 344.77
+4.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.51B
OE per share TTM
64.21
Owner's Yield
1.71%
Maintenance CapEx ratio
23.51%
Maint CapEx / Avg PPE
14.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 114 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Brown Advisory International Value Select ETF BAIV | 1.75% | 1.66M | 0.60% |
| 2 | State Street SPDR S&P Pan Asia Dividend Aristocrats UCITS ETF (Dist) ASDV.L | 0.54% | 1.31M | 0.55% |
| 3 | Innovator International Developed Managed Floor ETF IFLR | 0.13% | 112.7K | 0.89% |
| 4 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.12% | 666.7K | 0.58% |
| 5 | iShares MSCI Japan Small-Cap ETF SCJ | 0.11% | 283.0K | 0.50% |
| 6 | Schwab Fundamental International Small Company Index ETF FNDC | 0.09% | 2.57M | 0.39% |
| 7 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.06% | 459.7K | 0.23% |
| 8 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.06% | 459.9K | 0.23% |
| 9 | Avantis International Small Cap Equity ETF AVDS | 0.05% | 162.3K | 0.30% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.05% | 104.1K | 0.83% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
7.03M
Shares Outstanding
116.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroshi Sadakata | Chief Executive Officer, President & Representative Director | 90M | male |
| Kazuhiro Tsuruta | Chief of Office of President & GM of Sales Department | — | male |
| Yoshimitsu Sakai | GM of Store Development Department & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9989.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
